14 results
Primary:The primary objective of this study is to determine whether DMF taken over 12 months is effective in reducing MS-related fatigue, as measured by mean changes in the Fatigue Scale for Motor and Cognitive Functions (FSMC), in subjects with…
Our main objective is to prove that extending dose intervals guided by serum concentrations of natalizumab, will not result in radiological or clinical disease activity.
The objective of this study is to assess the distribution of infusion associated reactions (IARs) by severity grade when Lemtrada is administered to RRMS patients who will be medicated according to specified algorithm designed to manage infusion…
Immune regulation by dimethylfumarate (DMF) in patients with relapsing Remitting Multiple Sclerosis.
Primary objective: * Increases treatment with DMF the ability of Tregs to inhibit in relapsing-remitting MS patients? Proliferation of conventional T cells * Provides treatment with DMF to an increase in the number of nTreg (Foxp3 expression) or…
The primary objectives are to describe the disease course (conversion to clinically-definite multiple sclerosis [CDMS]), change in disability, cognitive function, resource use, and employment status, in relation to treatment with Interferon beta-1b…
In this double-blind randomized controlled trial, we would like to show that a five-day treatment course with 16mg/day oral dexamethason is effective in inducing recovery from an exacerbation of MS. The advantages of oral dexamethason over…
The research question which needs to be answered is: Is it feasible to recruit in 6 months a minimal of 20 patients with MS and bladder dysfunction to participate in an acupuncture study and are these patients compliant with the treatment and the…
To better understand the utilities of the new BETACONNECT device and characterize its contribution to adherence, we plan to prospectively follow-up MS patients using the device for 24 weeks.
To evaluate the long-term safety and efficacy of alemtuzumab, for patients already treated with this medicine in preceding clinical trials (CARE-MS I, CARE-MS II and CAMMS03409).
This study has been transitioned to CTIS with ID 2023-506543-41-00 check the CTIS register for the current data. This Extension study will evaluate the effectiveness and safety of ocrelizumab in MS patients who were previously enrolled in a Roche…
With this study we aim to prove that personalized B cell tailored ocrelizumab treatment is non-inferior in the suppression of MS disease activity (clinically and radiologically) compared to the standard (fixed 24 week interval) treatment.
To perform long-term pre-specified follow-up of patients undergoing aHSCT for refractory RRMS.
This study has been transitioned to CTIS with ID 2024-513105-31-00 check the CTIS register for the current data. Primary Objective: Our objective is to validate the safety, measured by radiological disease activity, of personalized extended interval…
synopsis:Primary:• To assess the health related quality of life (HRQoL) through the MSQoL-54 scale in highly-active relapsing multiple sclerosis (RMS) subjects treated with Mavenclad® for 2 years (24 months)Secondary:• To assess treatment…